Key result
Targeting metabolic pathways in PH offers emerging avenues for diagnosis and treatment.
Metabolic aberrations are crucial components of pulmonary hypertension, and targeting these pathways offers potential for improved diagnostic and therapeutic options.
Answers are grounded in this paper and cite their sources.
Metabolic targeting in pulmonary hypertension warrants prospective trials; leaves open clinical utility.
Pulmonary hypertension (PH) is an often-fatal vascular disease of unclear molecular origins. The pulmonary vascular remodelling which occurs in PH is characterised by elevated vasomotor tone and a pro-proliferative state, ultimately leading to right ventricular dysfunction and heart failure. Guided in many respects by prior evidence from cancer biology, recent investigations have identified metabolic aberrations as crucial components of the disease process in both the pulmonary vessels and the right ventricle. Given the need for improved diagnostic and therapeutic options for PH, the development or repurposing of metabolic tracers and medications could provide an effective avenue for preventing or even reversing disease progression. In this review, we describe the metabolic mechanisms that are known to be dysregulated in PH; we explore the advancing diagnostic testing and imaging modalities that are being developed to improve diagnostic capability for this disease; and we discuss emerging drugs for PH which target these metabolic pathways.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2017) conducted a review in Pulmonary hypertension. Metabolic tracers and medications was evaluated. Metabolic aberrations are crucial components of pulmonary hypertension, and targeting these pathways with emerging drugs and imaging modalities could provide effective avenues for diagnosis and treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: